ibex Q4 FY2026 slides: AI drives growth amid margin pressure

ibex reported fiscal Q4 revenue of $164.3 million, up 12% year over year and 7.1% above consensus, while adjusted EPS of $0.85 beat estimates by 7.6%; shares nevertheless fell 2.01% after hours to $36.51. Q4 adjusted EBITDA margin compressed 160bps to 12.3%, as EBITDA remained essentially flat at $20.2 million amid training, restructuring, fuel and delivery-transition costs. Fiscal 2027 guidance calls for revenue growth of 9%-11%, down from 15% in fiscal 2026, though management expects EBITDA margins to improve as temporary costs fade and AI-enabled service deployments scale.

Analysis

The central valuation question is whether AI raises IBEX’s revenue per client faster than it cannibalizes billable human-agent seats. Early deployments demonstrate commercial traction, but containment is not automatically accretive: customers will demand part of the labor savings, while IBEX must absorb integration, model-supervision, and sales costs. The investable proof point over the next 1-3 months is not further AI contract announcements, but sequential EBITDA-margin recovery alongside stable net revenue retention and new-logo conversion.

The offshore migration should create operating leverage once training cohorts normalize, but it also increases execution risk: wage inflation, FX moves, service-quality slippage, and geopolitical disruption can turn a purportedly temporary margin bridge into a permanent discount. Rising fuel and rates matter indirectly through client budgets, especially travel, retail, and smaller technology accounts; this makes the HealthTech mix the more durable source of multiple support. BJ is a modest read-through only—its AI deployment may validate retail demand, but it is not material enough to alter BJ’s earnings trajectory.

Consensus may be too focused on the headline growth deceleration and underweights the possibility that AI makes IBEX a higher-value, stickier workflow-integrator rather than a commoditized seat provider. Conversely, the low earnings multiple is not evidence of mispricing until management proves that AI-related revenue carries margins above legacy delivery; otherwise, the market is correctly assigning a transition discount. A sustained failure to expand EBITDA margin sequentially by the December-quarter report, or client-retention deterioration below historic levels, would falsify the constructive case.

Key Decisions for Investors

• Watch, do not chase IBEX immediately after the earnings reaction. Initiate a 1-3 month long only if management reiterates the full-year EBITDA range and the next reported quarter shows sequential margin expansion; target a rerating toward the prior 52-week trading range, with a stop on a close below the recent post-results low or a guidance cut.
• For a defined-risk expression, buy IBEX 3-6 month call spreads only if listed-option liquidity and open interest are adequate; use strikes around spot and 15-20% above spot. The thesis requires margin normalization, so premium at risk should be limited to the amount tolerable if AI revenue proves lower-margin than expected.
• Pair a prospective IBEX long against a short XRT or a small short in a discretionary-consumer-services proxy if macro data continue to tighten rate expectations. This isolates company-specific execution while reducing exposure to retail/travel customer-budget compression; cover the hedge if consumer spending or rate expectations reverse.
• Do not take a directional position in BJ on this development. Add BJ to an AI-productivity watchlist and reassess only when filings quantify labor-cost savings, digital conversion, or customer-service expense leverage attributable to the deployment.